GlobeNewswire: Prosensa Holding N.V. Contains the last 10 of 58 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T23:49:04ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2015/01/30/701606/10117842/en/Prosensa-Announces-Intent-to-Voluntarily-Delist-From-NASDAQ.html?f=22&fvtc=4&fvtv=19527Prosensa Announces Intent to Voluntarily Delist From NASDAQ2015-01-30T13:30:00Z<![CDATA[LEIDEN, The Netherlands, Jan. 30, 2015 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (Nasdaq:RNA) ("Prosensa" or the "Company"), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced today that it intends to voluntarily delist the registered shares of the Company, nominal value €0.01 per share (the "Shares"), from the NASDAQ Global Select Market ("NASDAQ"). Upon satisfaction of the applicable requirements for deregistration, Prosensa also intends to deregister the Shares under the Securities Exchange Act of 1934, as amended (the "Exchange Act") and to suspend its reporting obligations under the Exchange Act once it is eligible to do so.]]>https://www.globenewswire.com/news-release/2015/01/13/697049/10115367/en/Prosensa-Announces-Shareholder-Approval-of-Certain-Matters-Relating-to-the-BioMarin-Tender-Offer.html?f=22&fvtc=4&fvtv=19527Prosensa Announces Shareholder Approval of Certain Matters Relating to the BioMarin Tender Offer2015-01-13T13:41:26Z<![CDATA[Leiden, The Netherlands, Jan. 13, 2015 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical
company focusing on RNA-modulating therapeutics for rare diseases
with high unmet need, announced that during an extraordinary
general meeting of shareholders held today, Prosensa obtained
shareholder approval for certain matters relating to the previously
disclosed tender offer by BioMarin to purchase all of the
outstanding shares of Prosensa. ]]>https://www.globenewswire.com/news-release/2014/12/08/689405/10111387/en/Prosensa-Wins-Scrip-Biotech-Company-of-the-Year-2014-Award.html?f=22&fvtc=4&fvtv=19527Prosensa Wins Scrip 'Biotech Company of the Year' 2014 Award2014-12-08T13:00:00Z<![CDATA[Leiden, The Netherlands, Dec. 8, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical
company focusing on RNA-modulating therapeutics for rare diseases
with a high unmet medical need, is delighted to have won the Scrip
'Biotech Company of the Year' Award for 2014, announced last week
in London, UK.]]>https://www.globenewswire.com/news-release/2014/11/17/683690/10108528/en/Prosensa-Announces-3rd-Quarter-2014-Financial-Results-and-Recent-Corporate-Developments.html?f=22&fvtc=4&fvtv=19527Prosensa Announces 3rd Quarter 2014 Financial Results and Recent Corporate Developments2014-11-17T12:00:00Z<![CDATA[
LEIDEN, The Netherlands, Nov. 17, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (Nasdaq:RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today reported financial results for the third quarter ending September 30, 2014 and provided an update on the regulatory plans and re-dosing for drisapersen, our lead exon-skipping drug candidate, and next steps for our follow-on exon skipping compounds for the treatment of Duchenne muscular dystrophy (DMD).]]>https://www.globenewswire.com/news-release/2014/11/10/681603/10107318/en/Prosensa-Holding-N-V-to-Webcast-Conference-Call-Discussing-3rd-Quarter-2014-Financial-Results-and-Corporate-Update-on-November-17-2014.html?f=22&fvtc=4&fvtv=19527Prosensa Holding N.V. to Webcast Conference Call Discussing 3rd Quarter 2014 Financial Results and Corporate Update on November 17, 20142014-11-10T13:00:00Z<![CDATA[Leiden, The Netherlands, Nov. 10, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) today
announced that the Company will host a conference call and live
audio webcast on Monday, November 17, 2014 at 8:00
a.m. US Eastern Time (2:00 p.m. Central European Time) to
report its third quarter financial results and provide a corporate
update.]]>https://www.globenewswire.com/news-release/2014/11/07/681237/10107122/en/Prosensa-to-Present-at-Upcoming-Investor-Conferences.html?f=22&fvtc=4&fvtv=19527Prosensa to Present at Upcoming Investor Conferences2014-11-07T15:56:58Z<![CDATA[Leiden, The Netherlands, Nov. 7, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) today announced that Hans
Schikan, Chief Executive Officer, will present a corporate overview
at the following investor conferences:]]>https://www.globenewswire.com/news-release/2014/10/10/672323/10102170/en/Prosensa-begins-NDA-submission-to-the-FDA-for-exon-skipping-drug-drisapersen-to-treat-Duchenne-muscular-dystrophy.html?f=22&fvtc=4&fvtv=19527Prosensa begins NDA submission to the FDA for exon-skipping drug drisapersen to treat Duchenne muscular dystrophy2014-10-10T14:10:59Z<![CDATA[Leiden, The Netherlands, Oct. 10, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical
company focusing on RNA-modulating therapeutics for rare diseases
with high unmet need, today announced that it has commenced the
submission process for a New Drug Application (NDA) regulatory
filing to the United States Food and Drug Administration (FDA) for
its lead exon-skipping drug candidate, drisapersen, for treating
Duchenne muscular dystrophy (DMD). The drug received "Fast Track
status" from the FDA, making it eligible for a rolling review of an
NDA and was also granted "Breakthrough Therapy Designation" in June
2013.]]>https://www.globenewswire.com/news-release/2014/09/26/668712/10100162/en/Prosensa-extends-the-re-dosing-of-drisapersen-in-Europe-in-patients-with-Duchenne-muscular-dystrophy.html?f=22&fvtc=4&fvtv=19527Prosensa extends the re-dosing of drisapersen in Europe in patients with Duchenne muscular dystrophy2014-09-26T12:00:00Z<![CDATA[Leiden, The Netherlands, Sept. 26, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical
company focusing on RNA-modulating therapeutics for rare diseases
with high unmet need, today announced that it has extended its
comprehensive program of re-dosing of drisapersen in patients
with Duchenne muscular dystrophy (DMD) into Europe, with the
PRO051-02/DMD114673 sites re-opening, beginning with Belgium. This
follows quickly on the re-dosing program that began in the United
States (US) last week.]]>https://www.globenewswire.com/news-release/2014/09/25/668444/10099988/en/Prosensa-to-Present-at-Upcoming-Conferences.html?f=22&fvtc=4&fvtv=19527Prosensa to Present at Upcoming Conferences2014-09-25T12:00:00Z<![CDATA[Leiden, The Netherlands, Sept. 25, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) today announced that Hans
Schikan, Chief Executive Officer, will present a corporate overview
at the NewsMakers in the Biotech Industry Conference on Friday,
September 26 at 9:00am EDT and participate in a fireside chat at
the Leerink Partners Rare Disease Roundtable at 1:05pm EDT in New
York, NY. Live webcasts of the presentations can be accessed
through the Investors & Media section of the Prosensa corporate
website at ]]>https://www.globenewswire.com/news-release/2014/09/24/668133/10099857/en/Prosensa-publishes-a-sensitive-reproducible-and-objective-methodology-for-dystrophin-analysis-in-patients-with-Duchenne-muscular-dystrophy.html?f=22&fvtc=4&fvtv=19527Prosensa publishes a sensitive, reproducible and objective methodology for dystrophin analysis in patients with Duchenne muscular dystrophy2014-09-24T12:00:00Z<![CDATA[Leiden, The Netherlands, Sept. 24, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the
biopharmaceutical company focusing on RNA-modulating therapeutics
for rare diseases with high unmet need, today announced that the
results of its research into developing an accurate and
reproducible method for the measurement of dystrophin in patients
with Duchenne muscular dystrophy (DMD) and Becker's muscular
dystrophy (BMD) have been published in the online peer reviewed
journal PLOS ONE (]]>